Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma

Summary

Primary objective: To determine whether aspirin (ASA) can lower the incidence of Venous Thromboembolism(VTE) in patients with Glioblastoma (GBM). Secondary objectives: To determine clinical and laboratory factors which are associated with increased risk of VTE If it is determined that ASA reduces the incidence of VTE in patients with GBM, then to determine the clinical and laboratory factors which are associated with an increased benefit from the drug.

Timeline

Start

2008-11

Primary completion

2009-10

Completion

2009-10

Drugs

Indications